• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Ramelteon an Effective Hypnotic?

Is Ramelteon an Effective Hypnotic?

November 12, 2020
Randall Moore, MD, JD. and Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Randall Moore, MD, JD. Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences at Texas A&M Health Science Center College of Medicine. Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Moore and Dr. Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Ramelteon (Rozerem) stands out from other hypnotics in several ways:



  1. It is not a controlled substance and has no risk of addiction or ­withdrawal.

  2. It is relatively safe in the elderly.

  3. It has a low risk of falls and complex sleep behaviors.


However, ramelteon’s use has been limited by its high cost and modest efficacy. Now that it’s gone generic, we’ll look back on its 15-year tenure to figure out where this novel hypnotic stands.


How it works
Ramelteon is a synthetic analog of melatonin. It is an agonist at the melatonin receptors that regulate sleep and circadian rhythms and binds to them with greater affinity than natural melatonin. Those receptors are MT1 and MT2. MT1 promotes sleep by inhibiting wakefulness signals from the suprachiasmatic nucleus. MT2 synchronizes the circadian clock that regulates the 24-hour sleep cycle.


Tasimelteon (Hetlioz) has similar properties to ramelteon but is only FDA approved for insomnia in people whose circadian clocks are out of sync because of blindness.


A small but real effect
Compared to placebo, ramelteon helps patients with primary insomnia fall asleep 4–9 minutes faster (Kuriyama A et al, Sleep Med 2014;15(4):385–392). That might sound fairly unimpressive, but it’s only a few minutes behind the other hypnotics. It appears to work about as well as melatonin (0.5–5 mg qhs), but ramelteon has never gone head-to-head with another hypnotic, so all these comparisons are tentative and indirect.



Table: Hypnotics Compared


Table: Hypnotics Compared


(Click to view full-sized PDF.)



Given that ramelteon and melatonin are similar in efficacy and mechanism, why not just use melatonin as a hypnotic? Melatonin is a standard hypnotic in Europe, where it is regulated as a prescription product. However, in the US, melatonin is an over-the-counter supplement that is particularly vulnerable to quality control issues. When tested, 70% of melatonin products didn’t contain the amount on the label, with amounts that varied from 1/5th to 5 times the labeled amount (Erland LAE and Saxena PK, J Clin Sleep Med 2017;13(2):275–281). Melatonin’s half life (1 hour) is also much shorter than ramelteon’s (3 hours), but that problem can be improved with a sustained-release product. If your patient does go the melatonin route, reliable brands include1:



  • Sustained release: Member’s Mark (at Sam’s Club), Natrol, REMfresh, Source Naturals, and Dr. Wurtman’s (which is part SR, part IR).

  • Instant release: Life Extension, Nature Made, Natrol (at Costco), Swanson, Trader Darwin’s (at Trader Joe’s), and Walgreens Quick ­Dissolve


1These brands were certified by Consumer Labs or United States Pharmacopeia (USP), or were tested in clinical trials.


When it comes to long-term use, ramelteon has durable benefits, with no tolerance or withdrawal noted in controlled trials lasting up to 6 months and open-label studies up to 1 year. In some studies its benefits built up over weeks to months, which may be due to entrainment of the circadian system with nightly use. Benzodiazepines, and to a lesser extent the z-hypnotics, show some evidence of tolerance and withdrawal effects with long-term use (Neubauer DN, Neuropsychiatr Dis Treat 2008;4(1):69–79).


Ramelteon’s main advantage is in safety. It did not increase the risk of falls in trials that enrolled patients up to age 93. It is one of a few hypnotics that the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults do not flag as problematic in the elderly (the other safer hypnotics in this list include doxepin, suvorexant, lemborexant, and melatonin). Although all hypnotics carry a blanket warning about complex sleep behaviors, such as cooking or driving while asleep, these are not known to occur with ramelteon.


Ramelteon’s most common side effect is fatigue, but after a month it did not cause any more next-day sedation than placebo. Like other hypnotics, ramelteon can impair next-day driving. Other possible side effects include nausea, abdominal discomfort, headaches, and paradoxical insomnia (Neubauer, 2008).


Other benefits
Ramelteon has also been explored in bipolar disorder and delirium. Based on three randomized, placebo-controlled trials (n = 746), ramelteon may lower the risk of relapse into depression in bipolar disorder when started in manic or euthymic states, but this effect is very small—only 1 in 14 patients benefited (Kishi T et al, Neuropsychiatr Dis Treat 2019;15:1479–1486).


Both ramelteon and melatonin reduce the incidence of delirium in hospitalized patients at high risk for this syndrome, including postoperative patients. However, melatonin is probably more effective. Evidence supports either 0.5 or 5 mg of melatonin. In high-risk hospitalized patients, melatonin reduced the risk of delirium by 70%–80% (Yang CP et al, Sleep Med Rev 2020;50:101235).



Table: Ramelteon: At a Glance


Table: Ramelteon: At a Glance


(Click to view full-sized PDF.)



How to use it
Ideal candidates for ramelteon include the elderly, those at risk for falls or substance abuse, and patients who are likely to need a long-term hypnotic. The starting dose is the same as the max dose (8 mg qhs) and it can be taken nightly or as needed, about 30 minutes before bedtime. Patients should not take ramelteon too late because doing so might phase-delay the circadian rhythm (ie, turn patients into night owls). Ramelteon is an expensive generic, but most insurers cover it, and its price should fall soon as more generic competitors enter the market.


Patients may have trouble switching from other hypnotics to ramelteon, with its lower potency and lack of rewarding and anxiolytic properties. Cross-tapering may be necessary when changing from some hypnotics.


TCPR Verdict: With their modest benefits, the cardinal rule with sleep medications is to do no harm. Ramelteon fulfills that promise, but it’s not as potent as other hypnotics and may not be much better than melatonin.


 


podcastsTo learn more, listen to our 12/7/20 podcast, “CBT-Insomnia: A Patient Guide.” Search for “Carlat” on your podcast store.

General Psychiatry
KEYWORDS belsomra benzodiazepines geriatric-psychiatry hypnotics lemborexant melatonin sleep suvorexant
    Randall Moore, MD, JD.

    Nuplazid: Novel Mechanism, Modest Benefits

    More from this author
    Chris Aiken, MD.

    Prior Authorizations for Psychiatric Medications: A Primer for Frustrated Clinicians

    More from this author
    www.thecarlatreport.com
    Issue Date: November 12, 2020
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Practical Psychotherapy, TCPR, November/December 2020
    Is Ramelteon an Effective Hypnotic?
    Side Effects of Psychotherapy
    Brief Therapy During the Medication Visit
    How to Select an SSRI
    Metformin ER Recalled Due to Cancer Risk
    Chemical Exposures
    Beta Blockers and Depression: The Controversy Revisited
    Transcranial Direct-Current Stimulation in Depression Reconsidered
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.